Johnson & Johnson said CEO William Weldon is stepping down from that role in April, a move that ends Weldon's tenure during a period J&J has been beset by product recalls and lawsuits. FULL STORY »
Johnson & Johnson plans to pay $21.3 billion in cash and stock in part to capitalize on the expectation that an aging and heavier population will need more artificial parts. FULL STORY »
Switch to the new Modern Healthcare Daily News app
For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.
